Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Bevacizumab in Recurrent Glioblastoma
NCT00892177Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2009
- Primary completion
- Nov 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma multiforme (GBM) and glioma comparing Dasatinib + Bevacizumab with Placebo + Bevacizumab (2 arms). Primary endpoints: Maximum Tolerated Dose of Dasatinib at 14 days and Progression-Free Survival at 6 Months. Started Oct 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
glioblastoma multiforme (GBM)glioma
Beyond the preview
Go deeper on NCT00892177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892177.